Leukocyte (e.g., Lymphocyte, Granulocyte, Monocyte, Etc.) Patents (Class 435/7.24)
-
Publication number: 20150057176Abstract: The present invention provides methods for early diagnosis of Alzheimer's disease and for determining the efficacy of a treatment for Alzheimer's disease in an Alzheimer's patient, i.e., monitoring Alzheimer's disease progression, utilizing cellular blood markers; as well as kits for carrying out these methods.Type: ApplicationFiled: March 21, 2013Publication date: February 26, 2015Inventors: Michal Eisenbach-Schwartz, Ester Yoles
-
Publication number: 20150056636Abstract: The present invention provides a transgenic mouse which comprises a deficiency for murine T lymphocytes, B lymphocytes and NK cells, a deficiency for murine MHC class I and MHC class II molecules, and a functional xenogenic SIRP? transgene. This mouse is useful for in vivo screening of various compounds, including immuno-therapeutic agents and vaccines. The said mouse is also useful for testing the in vivo metabolism of xenobiotic compounds.Type: ApplicationFiled: March 26, 2013Publication date: February 26, 2015Inventors: Sylvie Garcia, Malika Serra-Hassoun
-
Patent number: 8961968Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: May 7, 2012Date of Patent: February 24, 2015Assignee: Genmab A/SInventors: Janine Schuurman, Catharina Emanuele Gerarda Havenith, Paul Parren, Jan G. J. Van De Winkel, Denise Leah Williams, Jørgen Petersen, Ole Baadsgaard
-
Patent number: 8962263Abstract: The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.Type: GrantFiled: April 26, 2011Date of Patent: February 24, 2015Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Omar D. Perez, Garry P. Nolan
-
Publication number: 20150051146Abstract: A ligand recombinant protein inhibiting HB-EGF (Heparin-Binding Epidermal Growth Factor like), from the R domain of diphtheria toxin, which can be used for the treatment and diagnosis of diseases involving the activation of the HB-EGF/EGFR pathway.Type: ApplicationFiled: March 19, 2013Publication date: February 19, 2015Applicant: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALTInventors: Daniel Gillet, Benoit Villiers, Sylvain Pichard, Bernard Maillere, Alain Sanson
-
Publication number: 20150050303Abstract: The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating and diagnosing celiac disease in a large proportion of patients.Type: ApplicationFiled: August 13, 2014Publication date: February 19, 2015Applicant: ImmusanT, Inc.Inventors: Robert P. Anderson, Jessica A. Stewart, James A. Dromey, Jason A. Tye-Din
-
Publication number: 20150050670Abstract: The current invention provides methods to identify ?9?2T-cell receptors (?9?2TCR) that mediate anti-tumour responses. Surprisingly, it was now found that the CDR3 regions of the ?9-T-cell receptor chain and the ?2-T-Cell receptor chain (?2TCR chain) are of importance. Based on these findings, combinatorial-??TCR-chain-exchange (CTE) is proposed as an efficient method for identifying ?9?2TCRs that mediate anti-tumour responses. Using the method of the invention, specific sequences of the respective ?9TCR and ?2TCR chains were identified that mediate anti-tumour responses. Hence, the invention further provides for specific ?9?2TCRs, or fragments thereof, that may be used e.g. in diagnostics or treatment of cancer. The invention further provides for nucleic acid sequences, genetic constructs and retroviral vectors that can be used to express the ?9?2TCRs according to the invention.Type: ApplicationFiled: March 28, 2013Publication date: February 19, 2015Inventors: Jürgen Herbert Ernst Kuball, Elsa-Cordula Gründer
-
Publication number: 20150044245Abstract: Disclosed herein are isolated major histocompatibility complex (MHC) class II ?1 domain polypeptides and methods of use. In some embodiments, the isolated polypeptide comprises or consists of an MHC class II ?1 domain polypeptide (or portion thereof) and does not include an MHC class II ?2, ?1, or ?2 domain. The disclosed MHC class II ?1 domain polypeptides are of use in treating or inhibiting disorders in a subject, such as inflammatory and/or autoimmune disorders. Also disclosed are methods of evaluating efficacy of treatment or optimizing treatment of a subject with a polypeptide including an MHC class II ?1 domain polypeptide (or portion thereof) or a polypeptide including an MHC class II ?1 domain and ?1 domain (such as a ?1?1 RTL).Type: ApplicationFiled: January 4, 2013Publication date: February 12, 2015Inventors: Arthur A. Vandenbark, Gregory G. Burrows, Roberto Meza-Romero, Gil Benedek, Shayne Andrew, Jeffery Mooney
-
Publication number: 20150044696Abstract: An integrated microfluidic device for carrying out a series of fluidic operations includes a housing including a plurality of n microfluidic conduits, wherein n is at least three, and a rotating valve having an internal channel with an entrance port and an exit port that are angularly separated. The rotating valve is positionable in a first position to connect two of the n fluidic conduits via the internal channel, and upon rotating the valve to a second position, two other of the n fluidic conduits are connected by the internal channel. The device further may include one or more fluidic chambers in fluid communication with respective fluidic conduits. Fluid contained in one fluidic chamber is transferrable by application of positive or negative gas pressure through associated fluidic conduits into another fluidic chamber via the internal channel. The device may be utilized to perform a variety of fluidic operations.Type: ApplicationFiled: August 9, 2013Publication date: February 12, 2015Applicant: SHARP KABUSHIKI KAISHAInventors: Pamela Ann DOTHIE, Daniel Christopher SPENCER
-
Publication number: 20150047061Abstract: Genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein are provided. Also provided are genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein that have been engrafted with human cells such as human hematopoietic cells, and methods for making such engrafted mice. These mice find use in a number of applications, such as in modeling human immune disease and pathogen infection; in in vivo screens for agents that modulate hematopoietic cell development and/or activity, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to hematopoietic cells; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on hematopoietic cells; in in vivo screens of human hematopoietic cells from an individual to predict the responsiveness of an individual to a disease therapy, etc.Type: ApplicationFiled: August 26, 2014Publication date: February 12, 2015Inventors: Andrew J. Murphy, Sean Stevens, Chozhavendan Rathinam, Elizabeth Eynon, Markus Manz, Richard Flavell, George D. Yancopoulos
-
Publication number: 20150044141Abstract: The present invention provides analog compounds of DPA-713 which specifically bind the translocator protein (TSPO), which is upregulated in activated leukocytes, some malignant tumors and tissues involved in steroid biogenesis. These compounds are linked via a linking moiety to a variety of imaging agents, including, for example, near infra-red dyes. The compounds of the present invention are useful for both pre-clinical near-IR fluorescence imaging (NIRF) and use in optically-guided interventions including NIRF endoscopy. Methods of use in diagnosis and treatment of TSPO related disease are also provided.Type: ApplicationFiled: March 14, 2013Publication date: February 12, 2015Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Martin Gilbert Pomper, Haofan Wang, Catherine Anne Foss
-
Patent number: 8951747Abstract: The invention relates to methods and compositions which modulate T lymphocyte activity. It has been found that two, T lymphocyte receptors, especially TCR and CD8, are present at a distance from each other on T lymphocyte surfaces. Via use of modulators which change the distance between these receptors, the activity of the T lymphocyte is modulated.Type: GrantFiled: March 26, 2012Date of Patent: February 10, 2015Assignee: Ludwig Institute for Cancer ResearchInventors: Nathalie Demotte, Pierre Van Der Bruggen, Thierry Boon-Falleur
-
Patent number: 8951793Abstract: Disclosed are methods of isolating and using a population of FOXP3+ regulatory T cells in a variety of preventative and therapeutic approaches to autoimmune diseases, graft-versus-host disease and transplant rejection.Type: GrantFiled: August 21, 2009Date of Patent: February 10, 2015Assignee: The United States of America, as represented by The Secretary, Department of Health and Human ServicesInventors: Dat Tran, Ethan M. Shevach
-
Publication number: 20150037819Abstract: A method for determining the quantity of anti-HLA antibodies of a liquid medium containing antibodies.Type: ApplicationFiled: February 15, 2013Publication date: February 5, 2015Applicants: UNIVERSITE PAUL SABATIER TOULOUSE III, INVIVOGEN, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Antoine Blancher, Nicolas Congy, Jean-Gerard Tiraby, Daniel Drocourt
-
Patent number: 8945857Abstract: The invention provides methods for isolating cells, particularly antibody-secreting cells that have a high likelihood of secreting antibodies specific for a desired antigen for the purpose of making monoclonal antibodies.Type: GrantFiled: June 30, 2006Date of Patent: February 3, 2015Inventor: John Schrader
-
Publication number: 20150031562Abstract: Biomarkers useful for identifying treatments for and monitoring treatment of patients with multiple sclerosis (MS) are provided, as well as methods for their identification, methods of diagnosing MS, relapse of MS patients and disease progression in MS patients.Type: ApplicationFiled: February 27, 2014Publication date: January 29, 2015Applicant: BIOGEN IDEC MA INC.Inventors: Aaron B. Kantor, Susan E. Goelz, Jun Deng, Hua Lin, Christopher Becker
-
Publication number: 20150031566Abstract: The invention demonstrates an improved choice of biotinylation peptide to be used in a combination or fusion with an MHC molecule for immobilizing or multimerising such MHC molecules for a variety of purposes.Type: ApplicationFiled: July 24, 2014Publication date: January 29, 2015Inventors: Catherine Elizabeth NAPPER, Nikolai Franz Gregor SCHWABE
-
Publication number: 20150031051Abstract: Methods, devices, apparatus, and systems are provided for image analysis. Methods of image analysis may include observation, measurement, and analysis of images of biological and other samples; devices, apparatus, and systems provided herein are useful for observation, measurement, and analysis of images of such samples. The methods, devices, apparatus, and systems disclosed herein provide advantages over other methods, devices, apparatus, and systems.Type: ApplicationFiled: October 7, 2014Publication date: January 29, 2015Inventors: Karan Mohan, Chinmay Pangarkar, James R. Wasson
-
Patent number: 8940494Abstract: Methods of assaying the leukocyte adhesion cascade (LAC) and monitoring leukocyte rolling, adhesion, and/or migration can be implemented with an apparatus that includes an idealized microvascular network (IMN) of one or more interconnected idealized flow channels in fluid communication through a porous wall with a tissue space (e.g., idealized tissue space). The methods of assaying the LAC can be implemented with means for quantifying modulation of the leukocyte adhesion cascade. Methods of assaying the LAC can be implemented with the device and one or more active agents to monitor leukocyte rolling, adhesion, and/or migration in the presence of absence of the active agent. Migration can be through the idealized flow channels, through the porous wall, and/or into the tissue space.Type: GrantFiled: January 16, 2013Date of Patent: January 27, 2015Assignee: CFD Research CorporationInventors: Balabhaskar Prabhakarpandian, Kapil Pant
-
Publication number: 20150024412Abstract: Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity Fc?R locus, and wherein the mouse is capable of expressing a functional FcR?-chain. Genetically modified mice are described, including mice that express low affinity human Fc?R genes from the endogenous Fc?R locus, and wherein the mice comprise a functional FcR?-chain. Genetically modified mice that express up to five low affinity human Fc?R genes on accessory cells of the host immune system are provided.Type: ApplicationFiled: October 7, 2014Publication date: January 22, 2015Inventors: Lynn Macdonald, Naxin Tu, Cagan Gurer, Li-Hsien Wang, Sean Stevens, Andrew J. Murphy
-
Publication number: 20150024411Abstract: The present invention relates to the chromatographic isolation of a target cell or another complex biological material, in particular by column chromatography such as affinity chromatography or gel permeation chromatography. The invention employs a receptor binding reagent that binds to a receptor molecule that is located on the surface of a target cell. The invention in general provides novel methods for the traceless isolation of biologic materials such as cells, cell organelles, viruses and the like. The invention also relates to an apparatus for the isolation of cells and other complex biological materials.Type: ApplicationFiled: February 25, 2013Publication date: January 22, 2015Inventor: Herbert Stadler
-
Publication number: 20150023991Abstract: The present invention concerns the field of tumor therapeutics and diagnostics. Specifically, it relates to a peptide comprising at least 8 amino acids in length which are present as contiguous amino acid sequence in the human Isocitratdehydrogenase Type 1 (IDH1), wherein said peptide has at least one amino acid exchange from R to H at a position corresponding to position 132, for use in preventing and/or treating cancer. Further contemplated is a medicament comprising the said peptide.Type: ApplicationFiled: January 3, 2013Publication date: January 22, 2015Inventors: Michael Platten, Theresa Schumacher, Wolfgang Wick
-
Publication number: 20150023938Abstract: Methods for preparing ex vivo T cell cultures using IL-21 compositions for use in adoptive immunotherapy are described. Addition of IL-21 to cultures of non-terminally differentiated T cells population, either isolated or present in peripheral blood mononuclear cells are exposed to one or more tumor antigens, and in the presence of IL-21 compositions and antigen presenting cells (APCs), the resulting T cell population has an enhanced antigen-specificity, and can be reintroduced into the patient. Methods are also disclosed for identifying tumor antigens by culturing T cell populations exposed to IL-21 compositions and APCs in the presence of tumor material.Type: ApplicationFiled: August 25, 2014Publication date: January 22, 2015Applicant: FRED HUTCHINSON CANCER RESEARCH CENTERInventor: Cassian Yee
-
Publication number: 20150024410Abstract: The invention relates to a method for detecting the binding of an antibody to an Fc receptor present on the surface of a cell as well as to a method for determining the level of glycosylation of an antibody. The invention also relates to a reagent kit for carrying out these methods.Type: ApplicationFiled: September 13, 2012Publication date: January 22, 2015Applicant: CISBIO BIOASSAYSInventors: Delphine Jaga, Hamed Mokrane, Stéphane Martinez, Michel Fink
-
Publication number: 20150017095Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: July 9, 2014Publication date: January 15, 2015Inventors: Tariq Ghayur, Jijie Gu, Peter Isakson
-
Patent number: 8933014Abstract: Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids.Type: GrantFiled: March 10, 2011Date of Patent: January 13, 2015Assignee: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Publication number: 20150011418Abstract: The present invention is a method for using levels of soluble Clusters of Differentiation (CD) proteins, or cell surface-localized CD proteins extracted from T lymphocytes for determining the immune status of a subject. The present invention also a kit containing a CD protein extraction means and at least one antibody which specifically binds a CD protein for use in carrying out the method of the invention.Type: ApplicationFiled: September 22, 2014Publication date: January 8, 2015Inventors: Jorn Gorlach, Jenifer Marie Gorlach
-
Publication number: 20150010923Abstract: The present invention relates to methods for labeling intracellular and extracellular targets of leukocytes, as well as to kits for performing said methods.Type: ApplicationFiled: December 21, 2012Publication date: January 8, 2015Inventors: Fabrice Malergue, Andreas Van Agthoven
-
Publication number: 20150010570Abstract: Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer.Type: ApplicationFiled: June 4, 2014Publication date: January 8, 2015Inventors: Richard J. Bucala, Lin Leng, Christine N. Metz
-
Publication number: 20150010591Abstract: The present invention provides in part peptides and polypeptides derived from Chlamydia app. The present invention also provides in part methods for treating, preventing or diagnosing Chlamydia infection using the peptides and polypeptides.Type: ApplicationFiled: October 1, 2012Publication date: January 8, 2015Inventors: Robert C. Brunham, Leonard James Foster
-
Publication number: 20150010924Abstract: The present invention relates to a method for diagnosis of delayed bone fracture healing, comprising determining the frequency of a subpopulation of CD8+ cells selected from a first group comprised of CD8+CD57+, CD8+CD28? and CD8+CD28?/CD57+, in a sample obtained from a subject. The present invention further relates to a system and a kit of parts for prediction and resulting options for preventing of delayed bone fracture healing.Type: ApplicationFiled: February 4, 2013Publication date: January 8, 2015Inventors: Georg Duda, Hans-Dieter Volk, Simon Reinke, Christian Meisel, Christian Kleber, Sven Geissler, Katharina Schmidt-Bleek
-
Patent number: 8927290Abstract: Provided herein are compositions comprising native and denatured human leukocyte antigens (HLA) and methods of making said compositions. Also provided herein are methods and kits for the detection of antibodies to native HLAs.Type: GrantFiled: February 16, 2011Date of Patent: January 6, 2015Assignee: One Lambda, Inc.Inventors: Adam Idica, Chun-Tsan Deng, Paul I. Terasaki
-
Publication number: 20150004176Abstract: The present specification discloses regulatory T cells, compositions including regulatory T cells, methods of identifying, isolating, enriching, obtaining, and/or expanding regulatory T cells or subset populations thereof, kits including components useful for performing such methods, and methods of treating an immune-based disorder in an individual by administering regulatory T cells or compositions comprising such regulatory T cells to an individual in need thereof.Type: ApplicationFiled: June 29, 2012Publication date: January 1, 2015Applicant: BECKMAN COULTER, INC.Inventor: Carlos A. Garcia Santana
-
Patent number: 8921321Abstract: The invention relates to therapeutic agents for use in the prevention or treatment of Alzheimer's disease. In particular the invention relates to use of inhibitors of cell cycle reentry and progression to the G1/S transition or inhibitors of progression of the cell cycle through the G1/S transition point in the prevention or treatment of Alzheimer's disease.Type: GrantFiled: November 30, 2012Date of Patent: December 30, 2014Assignee: Isis Innovation Ltd.Inventor: Zsuzsanna Nagy
-
Publication number: 20140377760Abstract: A method of obtaining stem cells includes (1) a subject (such as a human or an animal) taking or being subjected to an action, (2) after the subject taking or being subject to the action, the subject waiting for a predetermined time interval (such as between 30 minutes and 2 hours), (3) after the subject waiting for the predetermined time interval, taking a tissue sample (such as a peripheral blood of the subject) from the subject, and (4) collecting the stem cells from the tissue sample. The step of the subject taking or being subjected to the action may include the subject taking a herb medicine or an object containing fucoidan. The stem cells may be configured for a dental implant surgery. The stem cells may include a CD9(+), CD349(+) cell between 0.1 and 6.0 micrometers in size and/or a Lgr5(+) cell between 0.1 and 6.0 micrometers in size.Type: ApplicationFiled: June 23, 2014Publication date: December 25, 2014Inventors: James Wang, Steve K Chen, Mou-Shiung Lin, Yun Yen
-
Publication number: 20140370524Abstract: A method for producing an examination reagent includes adding a helper ligand to an unfolded receptor protein in an initial solution so as to provide a pre-solution of the examination reagent with a folded receptor protein. The folded receptor protein comprises a bonded helper ligand which can be exchanged with an examination peptide.Type: ApplicationFiled: January 3, 2013Publication date: December 18, 2014Inventors: Sebastien Hartmut Springer, Sunil Kumar Saini
-
Publication number: 20140371090Abstract: A method and kit for determining antibody sensitivity and quality of a clone cell stain. The method comprises: obtaining a solid-phase carrier, cells and an antibody; adsorbing the antibody on the solid-phase carrier; incubating the cells and the antibody; preserving cells bound with the antibody; and dyeing and counting the cells bound with the antibody, so as to determine the antibody sensitivity or the quality of the clone cell stain based on the cell count. The kit comprises components used in the method.Type: ApplicationFiled: June 30, 2014Publication date: December 18, 2014Inventors: Yumei Zhao, Lifang Dong, Ting Lei
-
Publication number: 20140369930Abstract: The present invention relates to a pharmaceutical composition comprising a cyclotide for use in immune suppression as well as to a method for immune suppression comprising the step of administering an effective amount of a pharmaceutical composition comprising such a cyclotide to a subject in need thereof. The present invention also relates to a pharmaceutical composition comprising a cyclotide for use in treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. Likewise, the present invention also relates to a method for treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation.Type: ApplicationFiled: December 21, 2012Publication date: December 18, 2014Inventors: Christian Werner Gruber, Carsten Gruendemann
-
Publication number: 20140371099Abstract: The invention relates to an in vitro method for the diagnosis and/or prognosis and/or evaluation of the progression of a chronic inflammatory lung disease in a subject, using the level of expression of the GPR15 G protein-coupled receptor gene as a biomarker for the disease.Type: ApplicationFiled: January 31, 2013Publication date: December 18, 2014Inventors: Nelly Frossard, Jacques Haiech, Christine Lehalle, Romain Kessler, Antoine Magnan, Pascal Chanez, Jean-Luc Galzi
-
Patent number: 8912385Abstract: The present invention relates to genetically altered hybridomas, myelomas and B cells. The invention also relates to utilizing genetically altered hybridomas, myelomas and B cells in methods of making monoclonal antibodies. The present invention also provides populations of hybridomas and B cells that can be utilized to make a monoclonal antibody of interest.Type: GrantFiled: November 17, 2009Date of Patent: December 16, 2014Assignee: University of Georgia Research Foundation, Inc.Inventor: Richard B. Meagher
-
Patent number: 8911952Abstract: This invention relates generally to integrin ligand discovery and to a method of integrin ligand discovery base upon induction of ligand-induced epitopes. Such ligands have the potential to be active agent as anti-inflammatory, anti-angiogenesis and/or anti-thrombotic agents and for the treatment of integrin mediated diseases and/or conditions.Type: GrantFiled: March 23, 2011Date of Patent: December 16, 2014Assignee: STC. UNMInventors: Alexandre Chigaev, Larry A. Sklar
-
Publication number: 20140363472Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising the steps consisting of i) determining the density of B cells at the invasive margin of the tumor (im) in a tumor tissue sample obtained from said patient, ii) comparing said density with a predetermined reference value and iii) providing a good prognosis when the density of B cells at the invasive margin of the tumor is higher than the predetermined reference value and a poor prognosis when the density of B cells at the invasive margin of the tumor is lower than the predetermined reference value.Type: ApplicationFiled: January 21, 2013Publication date: December 11, 2014Inventors: Jerome Galon, Franck Pages, Bernhard Mlecnik, Gabriela Bindea, Herve Fridman
-
Publication number: 20140357522Abstract: Whole cell, simultaneous target and drug-target assay using differentially labeled antibodies and flow cytometry. First antibody binds to total target and second antibody binds to the drug binding site of the target, thus drug binding will competitively inhibit the second antibody allowing for a competitive inhibition assay of drug-target binding. The assay allows for whole cell analysis and even analysis of mixed populations of cells, yet provides detailed kinetic assessment of drug activity.Type: ApplicationFiled: August 6, 2014Publication date: December 4, 2014Applicant: LABORATORY CORPORATION OF AMERICA HOLDINGSInventors: Norman B. Purvis, Gregory T. Stelzer
-
Publication number: 20140356362Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.Type: ApplicationFiled: August 13, 2014Publication date: December 4, 2014Inventors: NAGARAJ GOVINDAPPA, KEDARNATH SASTRY, MARIA MELINA SOARES
-
Publication number: 20140349312Abstract: The present invention relates to a culture support for cultivating hematopoietic stem cells (HSCs) and/or hematopoietic progenitors (HPs), comprising a calcium biomaterial, osteoclasts, endothelial cells and mesenchymatous stem cells (MSCs) and/or osteoblasts and/or adipocytes. The present invention also relates to a method for preparing such a culture support, and an in vitro HSC and/or HP cultivation method. The use of such a culture support for studying cellular mechanisms involved in hematopoiesis and/or differentiation of HSC/HPs and/or for studying the efficacy and/or the toxicity of a medicament candidate is also described.Type: ApplicationFiled: August 14, 2012Publication date: November 27, 2014Applicants: Institut Nationalde la Sante et de la Recherche Medicale (INSERM), ETAT FRANCAIS (MINISTERE DE LA DEFENSE), SERVICE DE SANTE DES ARMEESInventors: Jean-Jacques Lataillade, Marie-Caroline Le Bousse-Kerdiles
-
Publication number: 20140349314Abstract: The invention features methods of diagnosing inflammatory disease based on the elevated presence microparticles (MP) expressing certain receptors. The invention also features methods of decreasing fibrosis in the liver by administering MP to subjects with liver fibrosis.Type: ApplicationFiled: May 16, 2014Publication date: November 27, 2014Applicant: Beth Israel Deaconess Medical Center, Inc.Inventors: Detlef SCHUPPAN, Yury Popov, Miroslaw Kornek
-
Publication number: 20140349315Abstract: The present invention relates to disulphide bond stabilized recombinant MHC class II molecules. In particular, the present invention provides a recombinant MHC class II molecule, which comprises: (i) all or part of the extracellular portion of an MHC class II ? chain; (ii) all or part of the extracellular portion of an MHC class II ? chain; wherein (i) and (ii) provide a functional peptide binding domain and wherein (i) and (ii) are linked by a disulphide bond between cysteine residues located in the ?2 domain of said ? chain and the ?2 domain of said ? chain, wherein said cysteine residues are not present in native MHC class II ?2 and ?2 domains. Methods of producing these molecules in prokaryotic systems and various uses of these molecules form further aspects.Type: ApplicationFiled: July 14, 2014Publication date: November 27, 2014Applicant: Universitetet I OsloInventors: Geir Age Loset, Terje Frigstad, Inger Sandlie, Bjarne Bogen
-
Publication number: 20140349313Abstract: The present invention provides a method of identifying sub-populations of cells in a cellular sample. Aspects of the method include categorizing cells of the cellular sample into at least a first and second population based on a first phenotypic property. The method may further include sub-categorizing each of the first and second population into sub-populations of cells based on a second and third phenotypic property, e.g., by using X detectable labels providing Y distinct signals, wherein X>Y, to identify sub-populations of cells in the cellular sample.Type: ApplicationFiled: April 29, 2014Publication date: November 27, 2014Inventors: Robert Balderas, Mirko Corselli
-
Publication number: 20140342375Abstract: Described herein are microfluidic devices and methods that can greatly improve cell quality, streamline workflows, and lower costs. Applications include research and clinical diagnostics in cancer, infectious disease, and inflammatory disease, among other disease areas.Type: ApplicationFiled: March 14, 2014Publication date: November 20, 2014Applicants: UNIVERSITY OF MARYLAND, GPB SCIENTIFIC, LLC, THE TRUSTEES OF PRINCETON UNIVERSITYInventors: Michael Grisham, Curt I. Civin, James C. Sturm, Robert H. Austin
-
Publication number: 20140341915Abstract: The present invention is concerned with diagnostic methods and means. Specifically, it relates to an antibody which specifically binds to a portion of the extracellular domain of the B7-H6 polypeptide. Moreover, said antibody is provided for use in the treatment or diagnosis of cancer or inflammatory disease. Furthermore, provided are a method for diagnosing cancer in a sample of a subject suspected to suffer from cancer or an inflammatory disease. Further, the present invention concerns a device and a kit for diagnosing cancer or an inflammatory.Type: ApplicationFiled: September 10, 2012Publication date: November 20, 2014Inventors: Adelheid Cerwenka, Gerhard Moldenhauer